RECRUITING

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

Talk to us

Conditions

Metastatic Colorectal Cancer (Mcrc)Intrahepatic Cholangiocarcinoma (Icc)Colorectal CancerColorectal NeoplasmsCholangiocarcinomaIntrahepatic Bile Duct CancerBile Duct CancerBile Duct NeoplasmsMcrcIccNHS-IL12Response RatesProgression Free Survival (Pfs)Overall Survival (Os)Patient SurvivalUnresectable Liver TumorSMART System

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Background: One way to treat liver cancer is to deliver chemotherapy drugs only to the liver (and not to the whole body). Researchers want to see if adding the drug PDS01ADC can improve the treatment. The drug triggers the immune system to fight cancer.\<TAB\> Objective: To see if treatment with HAIPs to deliver liver-directed chemotherapy in combination with PDS01ADC is effective for certain cancers. Eligibility: People aged 18 and older who have cancer of the bile ducts that is only in the liver, or colorectal cancer that has spread to the liver. Design: Participants will be screened with: Medical history Physical exam Blood tests Pregnancy test (if needed) Tumor biopsy (if needed) Electrocardiogram Computed tomography (CT) scans Participants will have an abdominal operation. A catheter will be placed into an artery that feeds blood to the liver. The catheter will then be attached to the HAIP. The HAIP will lay under the skin on the left side of the abdomen. Participants will have chemotherapy drugs or heparin with saline infused into the HAIP every 2 weeks. PDS01ADC will be injected under the skin every 4 weeks. They will get systemic chemotherapy through an IV or mediport every 2 weeks. They will receive this treatment until their cancer gets worse or they have bad side effects. Participants will have 2 study visits each month. They will have CT scans every 8 weeks. At visits, they will repeat some screening tests. Participants will have a follow-up visit 1 month after treatment ends. Then they will be contacted every 6 months for 5 years.

Official Title

Phase II Study Evaluating the Efficacy of PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

Quick Facts

Study Start:2022-10-24
Study Completion:2028-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05286814

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age \>= 18 years.
  2. * Negative serum or urine pregnancy test at screening for individuals of childbearing potential (IOCBP).
  3. * All participants (regardless of gender or childbearing potential) must agree to use highly effective contraception prior to study entry, for the duration of study participation, and for 3 months after completion of study treatment for those able to father a child or 6 months after completion of study treatment for those of child-bearing potential (i.e., IOCBP). Highly effective birth control (failure rate of less than 1%), e.g., intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner and sexual abstinence. Note: The use of condoms by participants who are able to get other individuals pregnant is required unless the partner of childbearing potential is permanently sterile.
  4. * Nursing (including breastfeeding) participants must agree to discontinue nursing.
  5. * Arterial anatomy on CT angiogram or CT chest, abdomen and pelvis multiphase (i.e., CT C/A/P multiphase) amenable to placement of the HAIP.
  6. * Participant must sign the informed consent form to participate in this study.
  7. * HIV-positive participants may be considered for this study only if they have an undetectable viral load.
  8. * Participants must agree to co-enroll on the Surgical Oncology Program s tissue collection protocol 13C0176, Tumor, Normal Tissue and Specimens from Patients Undergoing Evaluation or Surgical Resection of Solid Tumors .
  9. * Participant s liver metastases must not be amenable to resection/ablation to No Evidence of Disease (NED) in one stage.
  10. * Participant must be able to tolerate systemic chemotherapy at initiation of study treatment as outlined below (mCRC: FOLFOX or FOLFIRI; ICC: GemOx or FOLFOX; ACC: GemOx).
  11. * Participants must have histologically or cytologically confirmed diagnosis of colorectal adenocarcinoma metastatic to the liver (Cohort 1).
  12. * Participants must have measurable liver metastatic disease.
  13. * Participants must have received 1st line systemic chemotherapy.
  14. * ECOG performance status \<= 1.
  15. * Participants must have adequate organ and marrow function as defined below:
  16. * leukocytes \> 3,000/mcL
  17. * absolute neutrophil count \> 1,500/mcL
  18. * platelets \> 90,000/mcL
  19. * hemoglobin \> 8 g/dL
  20. * total bilirubin \< 1.5 X institutional upper limit of normal
  21. * AST(SGOT)/ALT(SGPT) \< 2.5 X institutional upper limit of normal
  22. * creatinine within normal institutional limits OR eGFR within normal as predicted by the CKD-EPI equation \> 60 mL/min/1.73 m2.
  23. * Participants must have histologically or cytologically confirmed diagnosis of intrahepatic cholangiocarcinoma confined to the liver (Cohort 2). Archival tumor sample may be used but if archival tissue is not available or is not adequate, tissue biopsy will be required.
  24. * Clinical or radiographic evidence of metastatic disease to regional (porta hepatis) lymph nodes will be allowed, provided it is amenable to resection.
  25. * Participants must have radiographically measurable disease.
  26. * Disease must be considered unresectable at the time of preoperative evaluation.
  27. * Participants must have received 1st line systemic chemotherapy.
  28. * ECOG performance status \<=1.
  29. * Participants must have adequate organ and marrow function as defined below:
  30. * leukocytes \>= 2,000/ mm\^3
  31. * absolute neutrophil count \> 1,500/mcL
  32. * platelets \>= 75,000/ mm\^3
  33. * hemoglobin \> 8 g/dL
  34. * total bilirubin \< 1.5 mg/dl
  35. * creatinine \<= 1.5 mg/dl
  36. * Participants must have histologically or cytologically confirmed diagnosis of adrenocortical carcinoma (ACC), also referred to as adrenocortical cancer .
  37. * Participants must have received at least one line of systemic chemotherapy.
  38. * Participants must have measurable liver metastatic disease.
  39. * ECOG performance status \<= 1.
  40. * Participants must have adequate organ and marrow function as defined below:
  41. * leukocytes \> 3,000/mcL
  42. * absolute neutrophil count \> 1,500/mcL
  43. * platelets \> 90,000/mcL
  44. * hemoglobin \> 8 g/dL
  45. * total bilirubin \< 1.5 X institutional upper limit of normal
  46. * AST(SGOT)/ALT(SGPT) \< 3 X institutional upper limit of normal
  47. * creatinine \< 2 X institutional upper limit of normal
  1. * Participants who have previously received rIL-12.
  2. * Participants with active autoimmune diseases, that might deteriorate when receiving an immunostimulatory agent with the exceptions:
  3. * diabetes type I, vitiligo, alopecia, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible;
  4. * participants requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses \<= 10 mg of prednisone or equivalent per day;
  5. * administration of steroids for other conditions through a route known to result in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation) is eligible.
  6. * History of organ transplant, except for transplants that do not require immunosuppression.
  7. * History of or active inflammatory bowel disease (e.g., Crohn s disease, ulcerative colitis).
  8. * Known hypersensitivity or allergic reactions attributed to any compounds of similar chemical or biologic composition to the study medication, such as recombinant IL-12 or other monoclonal antibodies and history of allergic reactions attributed to compounds of similar chemical composition to FUDR or heparin.
  9. * Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke \< 6 months prior to enrollment, myocardial infarction \< 6 months prior to enrollment, unstable angina, congestive heart failure (\>= NYHA III) or serious cardiac arrhythmia requiring medication.
  10. * All conditions associated with significant necrosis of nontumor-bearing tissues.
  11. * Esophageal or gastroduodenal ulcers \< 6 months prior to treatment.
  12. * Active ischemic bowel disease.
  13. * Psychiatric illness/social situations that would limit compliance with study requirements.
  14. * Active concurrent malignancies within the last five years other than colorectal primary except basal cell skin carcinoma and thyroid carcinoma.
  15. * Prior radiation to liver.
  16. * Participants with active Hepatitis B or C infection.
  17. * Significant acute or chronic infections (i.e., tuberculosis) history of exposure or history of positive tuberculosis test; plus, presence of clinical symptoms, physical or radiographic findings).
  18. * Any condition, including the presence of laboratory abnormalities and/or insufficient normal liver parenchyma, which places the participant at unacceptable risk if they were to participate in the study or confounds the ability to interpret data from the study.
  19. * Participants who have undergone extra-hepatic metastasectomy and have a documented disease-free interval less than or equal to 4 months.
  20. * Participants with a history of MSI-high results who need to be treated with check-point inhibitors.
  21. * Prior treatment with FUDR.
  22. * Prior treatment with FUDR.
  23. * Diagnosis of sclerosing cholangitis.
  24. * Clinical evidence or portal hypertension (ascites, gastroesophageal varices, or portal vein thrombosis).
  25. * Participants with incontrovertible radiographic evidence of additional abdominal disease outside of the liver (including the primary tumor) that is not amenable to complete surgical extirpation at the time of pump placement.
  26. * Clinical evidence or portal hypertension (ascites, gastroesophageal varices, or portal vein thrombosis).
  27. * Diagnosis of sclerosing cholangitis.
  28. * Participants with pulmonary metastases that have progressed by RECIST criteria in the preceding 3 months prior to study enrollment.
  29. * Participants with known mismatch repair mutation who have not been treated with a checkpoint inhibitor. Acceptable methods of MSI testing for history of MSI results include immunohistochemistry (IHC) and next generation sequencing (NGS) of tumor material.

Contacts and Locations

Study Contact

Cathleen E Hannah, C.R.N.P.
CONTACT
(240) 858-7006
cathleen.hannah@nih.gov
Jonathan M Hernandez, M.D.
CONTACT
(240) 760-6072
jonathan.hernandez@nih.gov

Principal Investigator

Jonathan M Hernandez, M.D.
PRINCIPAL_INVESTIGATOR
National Cancer Institute (NCI)

Study Locations (Sites)

National Institutes of Health Clinical Center
Bethesda, Maryland, 20892
United States

Collaborators and Investigators

Sponsor: National Cancer Institute (NCI)

  • Jonathan M Hernandez, M.D., PRINCIPAL_INVESTIGATOR, National Cancer Institute (NCI)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-10-24
Study Completion Date2028-12-31

Study Record Updates

Study Start Date2022-10-24
Study Completion Date2028-12-31

Terms related to this study

Keywords Provided by Researchers

  • Mcrc
  • Icc
  • NHS-IL12
  • Response Rates
  • Progression Free Survival (Pfs)
  • Overall Survival (Os)
  • Patient Survival
  • Unresectable Liver Tumor
  • SMART System

Additional Relevant MeSH Terms

  • Metastatic Colorectal Cancer (Mcrc)
  • Intrahepatic Cholangiocarcinoma (Icc)
  • Colorectal Cancer
  • Colorectal Neoplasms
  • Cholangiocarcinoma
  • Intrahepatic Bile Duct Cancer
  • Bile Duct Cancer
  • Bile Duct Neoplasms